Europe clamps down on prices of orphan drugs

04/8/2013 | Bloomberg

Cash-strapped European governments have been balking at high prices for drugs to treat rare diseases, sometimes winning significant price concessions from manufacturers. Payers in the U.S. are likely to follow suit, says Mary Dunkle, a vice president at patient advocacy group National Organization for Rare Disorders. Thirteen European Union members are considering a plan to collaborate on cost-benefit analyses of orphan drugs, which might increase access across Europe, says Richard Bergstrom, director general of the European Federation of Pharmaceutical Industries and Associations.

View Full Article in:

Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC